Tempus AI Inc. (NASDAQ: TEM) shares surged over 11% on Friday, significantly outperforming broader market indices including the Nasdaq Composite, which rose 0.86%, and the S&P 500, which gained 0.47%. The stock’s sharp advance also eclipsed the Healthcare sector’s modest 0.3% gain, reflecting investor enthusiasm for artificial intelligence applications in healthcare technology.

The primary catalyst for Tempus AI’s price movement was a broader sector-wide rally triggered by stellar earnings and guidance from industry peers, notably Doximity Inc. (NYSE: DOCS). Doximity reported fiscal first-quarter revenue of $156.6 million, beating consensus analyst estimates of $151.7 million. During the earnings call, Doximity CEO Jeff Tangney stated that AI is "up-leveling our business across the board" and noted that the market opportunity unlocked by AI "has been a real surprise and upside for us."

Strategic Collaboration with CellCarta

Adding to the positive momentum, Tempus AI announced a strategic collaboration with CellCarta on Thursday, August 6. Under the agreement, CellCarta added Tempus to its CDx Commercialization Lab Network as its second commercial laboratory partner. This partnership aims to support oncology companion diagnostics offerings to biopharma sponsors, expanding Tempus’s reach in the diagnostic space.

Technical Analysis and Key Levels

From a technical perspective, Tempus AI shares were trading at $50.95 at the time of publication, representing a 10.49% increase. The stock is currently trading approximately 5% above its 20-day Simple Moving Average (SMA) of $48.15, signaling a shift in near-term trend direction. However, longer-term pressure remains evident as the stock trades about 13% below its 200-day SMA of $58.31.

The Relative Strength Index (RSI) stands at 53.87, indicating neutral momentum rather than an overbought condition. Traders are watching the 50-day SMA of $51.11 closely; the stock sits just 1.1% below this level, making it a critical threshold for determining whether the current bounce can evolve into a sustained upward trend.

Market Context and Outlook

Despite the short-term gains, the longer-term technical backdrop remains mixed-to-bearish. The 20-day SMA remains below the 50-day SMA, and a death cross formed in January suggests that rallies may encounter overhead supply. Historical context shows significant sentiment swings, with overbought conditions observed in October 2025 and oversold conditions in March. Investors will monitor whether the current momentum can overcome these technical headwinds and establish a new baseline above key resistance levels.

Tempus AI, Inc. (NASDAQ: TEM) announced the publication of study results in Nature Medicine demonstrating that its PRISM2 Pathology Foundation Model performs clinically important diagnostic tasks with high precision. Developed in collaboration with Microsoft, the multimodal slide-level model outperformed or matched existing foundation models across a comprehensive set of diagnostic, biomarker, and patient outcome prediction tasks. This development is significant for precision oncology as it enables the prediction of long-term outcomes, including colorectal cancer recurrence-free survival, without requiring specialized fine-tuning for complex research tasks.

The findings highlight the technical capabilities of PRISM2 as part of Tempus’ proprietary Pathology Foundation Models. The model transforms routine hematoxylin and eosin (H&E) slides into deep biological insights by combining large vision models built from pathology images with large language models. This multimodal approach unlocks diagnostic-grade precision in research involving cancer detection, biomarker identification, and prognosis prediction. Razik Yousfi, Senior Vice President and General Manager of AI Products at Tempus, stated that PRISM2 represents a leap forward in scale and multi-modal AI capabilities.

PRISM2’s performance is underpinned by its extensive training data. The model was trained on a diverse set of 2.3 million whole-slide images and 14 million diagnostic question-answer pairs derived from nearly 700,000 pathology reports. This dataset is described as the largest multimodal slide-level pathology dataset to date. By aligning whole-slide pathology images with the language of clinical diagnosis through clinical dialogue training, the model can seamlessly handle complex diagnostic and prognostic research tasks.

Key Training Data Metrics

According to management, the Pathology Foundation Models allow for a detailed understanding of tissue, unlocking clinical-grade precision and novel research applications. These applications are capable of predicting patient outcomes and biomarker status. The ability to predict colorectal cancer recurrence-free survival with high performance when further tuned specifically for long-term outcomes distinguishes PRISM2 from standalone models.

To support ongoing research, open science, and other non-commercial and non-clinical use cases, the full PRISM2 model weights are publicly available through Hugging Face. This accessibility aims to facilitate broader adoption and validation within the scientific community.

What the Numbers Show

The scale of the training data directly correlates with the model's reported versatility. With 14 million diagnostic question-answer pairs derived from nearly 700,000 reports, the dataset density suggests a robust alignment between visual pathology features and clinical language. This large-scale multimodal training allows PRISM2 to perform across multiple task types—diagnostic, biomarker, and prognostic—without specialized fine-tuning, indicating a generalizable architecture rather than a narrow, task-specific tool.